P53 germline mutations in childhood cancers and cancer risk for carrier individuals

A Chompret, L Brugières, M Ronsin, M Gardes, F Dessarps-Freichey, A Abel, D Hua, L Ligot, M G Dondon, B Bressac-de Paillerets, T Frébourg, J Lemerle, C Bonaïti-Pellié, J Feunteun, A Chompret, L Brugières, M Ronsin, M Gardes, F Dessarps-Freichey, A Abel, D Hua, L Ligot, M G Dondon, B Bressac-de Paillerets, T Frébourg, J Lemerle, C Bonaïti-Pellié, J Feunteun

Abstract

The family history of cancer in children treated for a solid malignant tumour in the Paediatric Oncology Department at Institute Gustave-Roussy, has been investigated. In order to determine the role of germline p53 mutations in genetic predisposition to childhood cancer, germline p53 mutations were sought in individuals with at least one relative (first- or second-degree relative or first cousin) affected by any cancer before 46 years of age, or affected by multiple cancers. Screening for germline p53 mutation was possible in 268 index cases among individuals fulfilling selection criteria. Seventeen (6.3%) mutations were identified, of which 13 were inherited and four were de novo. Using maximum likelihood methods that incorporate retrospective family data and correct for ascertainment bias, the lifetime risk of cancer for mutation carriers was estimated to be 73% for males and nearly 100% for females with a high risk of breast cancer accounting for the difference. The risk of cancer associated with such mutations is very high and no evidence of low penetrance mutation was found. These mutations are frequently inherited but de novo mutations are not rare.

References

    1. Am J Hum Genet. 1999 Oct;65(4):995-1006
    1. Schweiz Med Wochenschr. 1993 Jun 26;123(25):1287-92
    1. Cancer Res. 1988 Sep 15;48(18):5358-62
    1. Cancer Res. 1991 Nov 15;51(22):6094-7
    1. Am J Epidemiol. 1992 Jan 15;135(2):190-9
    1. N Engl J Med. 1992 May 14;326(20):1301-8
    1. Nat Genet. 1993 Oct;5(2):124-9
    1. Oncogene. 1994 Jan;9(1):97-102
    1. Cancer Res. 1994 Mar 1;54(5):1298-304
    1. J Clin Oncol. 1994 May;12(5):925-30
    1. Cancer Detect Prev. 1994;18(3):171-8
    1. Biochim Biophys Acta. 1994 Dec 30;1198(2-3):197-213
    1. Hum Mol Genet. 1994 Dec;3(12):2247-8
    1. Am J Hum Genet. 1995 Mar;56(3):608-15
    1. Genet Epidemiol. 1995;12(1):13-25
    1. Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3963-7
    1. Oncogene. 1996 Jun 6;12(11):2437-42
    1. Br J Cancer. 1996 Jul;74(2):269-73
    1. Cancer Surv. 1995;25:101-24
    1. Oncogene. 1997 Apr 17;14(15):1869-74
    1. Br J Cancer. 1997;76(1):1-14
    1. Lancet. 1997 Jul 12;350(9071):91-5
    1. Cancer Res. 1997 Aug 1;57(15):3245-52
    1. N Engl J Med. 1992 May 14;326(20):1309-15
    1. Am J Hum Genet. 1992 Aug;51(2):344-56
    1. Cancer Res. 1993 Feb 1;53(3):452-5
    1. Oncogene. 1993 May;8(5):1203-10
    1. Oncogene. 1993 May;8(5):1269-76
    1. Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3

Source: PubMed

3
Předplatit